{"id":"cis-uca-ophthalmic-solution-2-5","_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T02:30:46.345Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123219,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"cyclosporine ophthalmic emulsion","brand":"Restasis","company":"AbbVie","rationale":"Approved immunomodulatory treatment for dry eye disease"},{"name":"lifitegrast ophthalmic solution","brand":"Xiidra","company":"Novartis","rationale":"Approved LFA-1 antagonist for dry eye disease"},{"name":"varenicline nasal spray","brand":"Tyrvaya","company":"Viatris","rationale":"Approved nicotinic acetylcholine receptor agonist for dry eye"}],"description":"Cis-UCA ophthalmic solution 2.5% is an investigational eye drop developed by Herantis Pharma for the treatment of dry eye disease. The drug is currently in Phase 2 clinical development as a potential therapeutic option for patients with this common ocular surface disorder.","indications":{"approved":[{"status":"investigational","condition":"Dry eye disease","patientPopulation":"Adult"}]},"trialDetails":[{"nctId":"NCT02326090","phase":"PHASE2","title":"Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye","status":"COMPLETED","sponsor":"Herantis Pharma Plc.","startDate":"2014-12","conditions":"Dry Eye Syndrome","enrollment":161},{"nctId":"NCT01476332","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers (Phase I)","status":"COMPLETED","sponsor":"Laurantis Pharma, Ltd.","startDate":"2011-11","conditions":"Dry Eye","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"cis-UCA ophthalmic solution 2.5%","genericName":"cis-UCA ophthalmic solution 2.5%","companyName":"Herantis Pharma Plc.","companyId":"herantis-pharma-plc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}